Your browser is no longer supported. Please, upgrade your browser.
RLM Realm Therapeutics Plc daily Stock Chart
Realm Therapeutics Plc
Index- P/E- EPS (ttm)-2.92 Insider Own31.10% Shs Outstand4.66M Perf Week1.05%
Market Cap17.90M Forward P/E- EPS next Y- Insider Trans- Shs Float1.99M Perf Month-6.34%
Income- PEG- EPS next Q- Inst Own46.35% Short Float0.97% Perf Quarter66.96%
Sales0.25M P/S70.67 EPS this Y- Inst Trans- Short Ratio0.66 Perf Half Y36.17%
Book/sh4.58 P/B0.84 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.35 - 13.00 Perf YTD107.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.46% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low184.44% ATR0.24
Employees8 Current Ratio- Sales Q/Q-49.50% Oper. Margin- RSI (14)53.27 Volatility2.75% 4.88%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.01 Prev Close3.68
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume29.11K Price3.84
Recom- SMA20-1.83% SMA5011.51% SMA20030.55% Volume150 Change4.35%
Apr-10-19 07:00AM  Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing PR Newswire
Apr-05-19 04:05PM  Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests Hearing PR Newswire +5.40%
Mar-29-19 07:00AM  Realm Therapeutics Announces Completion of Assets Disposal PR Newswire
Mar-28-19 03:04PM  Malvern biopharm firm to shed assets in $10M deal American City Business Journals
Mar-26-19 07:00AM  Realm Therapeutics Announces Cancellation of AIM Listing PR Newswire
Mar-15-19 10:36AM  Realm Therapeutics Announces Result of General Meeting PR Newswire +8.97%
Feb-15-19 02:20PM  Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company"), Update on Strategic Review, Proposed Assets Disposal, Proposed Adoption of Investing Policy, Proposed AIM Delisting and Notice of General Meeting PR Newswire +16.16%
Dec-20-18 04:32AM  Our Take On Realm Therapeutics Plcs (LON:RLM) CEO Salary Simply Wall St. -20.85%
Nov-29-18 11:42AM  Healthcare Stocks Continue To Rally Amid Volatile Market Conditions; Premier Health Group, Inc. (PHGRF) (PHGI), Inovalon Holdings, Community Health Systems, Realm Therapeutics ACCESSWIRE +21.62%
07:00AM  Realm Therapeutics Provides Update on Strategic Review PR Newswire
Sep-19-18 08:00AM  Todays Research Reports on Stocks to Watch: Viking Therapeutics and Realm Therapeutics ACCESSWIRE -21.88%
Sep-17-18 07:24AM  Realm Therapeutics launches review that may include a sale after disappointing trial results MarketWatch -10.00%
07:00AM  Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process PR Newswire
Aug-14-18 07:18AM  Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial Results PR Newswire
Aug-08-18 07:00AM  Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-07-18 07:00AM  Realm Therapeutics to Report First Half 2018 Financial Results PR Newswire
Jul-10-18 07:00AM  Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis PR Newswire
Jul-04-18 07:01AM  Realm Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs PR Newswire
07:00AM  Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares PR Newswire
Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.